Overview
Preclinical Personalized Neoantigen mRNA Vaccine Development for Precision Oncology Research
Personalized neoepitope mRNA cancer vaccinesare designed to encode tumor-specific mutant epitopes identified from an individual tumor's mutanome. The scientific appeal is clear: neoepitopes are absent from normal tissues, can reduce the risk of central tolerance, and may support focused T-cell priming against biologically relevant tumor mutations.
- Practical questions faced at the project design stage:
- Which sequencing and bioinformatics workflow is most appropriate for neoantigen discovery?
- How should candidate epitopes be ranked beyond simple MHC binding prediction?
- What mRNA architecture is most suitable for robust antigen expression?
- Which delivery strategy is best aligned with the desired preclinical model?
- How should potency, immune activation, and anti-tumor activity be evaluated?
These issues matter because personalized cancer vaccine research is constrained by tumor heterogeneity, variable antigen processing, uncertain T-cell immunogenicity, and the technical difficulty of balancing mRNA expression, innate sensing, delivery efficiency, and formulation stability. Recent reviews emphasize that accurate neoantigen prioritization, construct optimization, and delivery design remain key hurdles in personalized vaccine R&D.
Featured Services
Tumor-Informed Neoepitope Discovery and Prioritization Services
We help research teams move from raw tumor-normal sequencing information to a prioritized neoepitope shortlist. Our workflow can support mutation calling, expression-informed filtering, HLA-aware prediction, and ranking strategies that consider more than peptide-MHC affinity alone.
Service Highlights
Personalized mRNA Construct Design and IVT mRNA Production Support
Once candidate neoepitopes are selected, we design research-grade mRNA constructs to match your preclinical goals. Depending on the study hypothesis, this may include multiepitope cassette design, linker strategy, sequence engineering, codon optimization, and UTR/poly(A) considerations.
Service Highlights
Formulation and Delivery Strategy Development
Delivery is often the difference between a promising concept and a weak dataset. We support preclinical formulation development for personalized mRNA vaccine candidates, including LNP-oriented research strategies.
Service Highlights
In Vitro Immunogenicity and Mechanism-of-Action Assessment
A personalized vaccine program needs more than a sequence file and a vial. We offer in vitro research services to evaluate whether your construct behaves as intended at the cellular and immunological levels.
Service Highlights
In Vivo Proof-of-Concept Studies in Preclinical Models
For clients requiring integrated biological validation, we support preclinical efficacy-oriented study design in appropriate research models.
Service Highlights
How We Advance Your Project
Step 1 — Project Definition
Tumor type, sample context, available sequencing data, HLA information, study model, and research objective alignment.
Step 2 — Neoepitope Identification
Mutation mining, candidate filtering, expression-aware ranking, and immunogenicity-centered prioritization.
Step 3 — mRNA Construct Engineering
Epitope cassette design, sequence optimization, structural review, and IVT readiness assessment.
Step 4 — Research-Grade mRNA Preparation
IVT synthesis planning, purification path selection, and analytical checkpointing.
Step 5 — Formulation Feasibility
Delivery system screening, comparability review, and early developability assessment.
Step 6 — Preclinical Immune Evaluation
In vitro assays, in vivo immunogenicity studies, cytokine/T-cell profiling, and mechanism-oriented data integration.
Step 7 — Candidate Down-Selection
Go/no-go recommendations based on expression, delivery, immune activation, and preclinical fit.
| Stage | What Clients Need | Our Preclinical Support |
|---|---|---|
| Discovery | Convert complex omics output into usable candidates | Mutation-informed neoepitope identification and prioritization |
| Design | Build a rational vaccine construct | Personalized multiepitope mRNA design and optimization |
| Production | Generate research-ready material | IVT mRNA support and analytical characterization |
| Delivery | Improve biological performance | Formulation and delivery screening |
| Validation | Confirm mechanism and activity | In vitro immunogenicity and expression testing |
| Decision | Know whether to advance, refine, or stop | In vivo proof-of-concept and integrated interpretation |
Our Proprietary Biotechnology Platforms
NeoScreen AI Algorithm
Unlike standard prediction tools, NeoScreen incorporates multi-dimensional parameters including peptide cleavage probability, TAP transport efficiency, and TCR recognition propensity.
TransMax mRNA Architecture
Highly optimized UTR sequences clinically proven to extend mRNA half-life by up to 300% compared to standard beta-globin UTRs.
LipoTarget Delivery Matrix
A bespoke library of novel ionizable lipids designed to target draining lymph nodes while minimizing hepatic off-target accumulation.
Research Insight: Personalized RNA Neoantigen Vaccines for PDAC
Clinical Proof-of-Concept in Pancreatic Cancer (PDAC)
-
Therapeutic Challenge: Pancreatic ductal adenocarcinoma (PDAC) is highly lethal with an 88% mortality rate, often characterized by "cold" tumor microenvironments that are insensitive to conventional checkpoint inhibitors.
-
Intervention Strategy: A Phase I trial utilized autogene cevumeran, an individualized uridine mRNA-lipoplex (RNA-LPX) vaccine encoding up to 20 patient-specific neoantigens, combined with atezolizumab and mFOLFIRINOX chemotherapy.
-
Manufacturing Feasibility: Real-time sequencing and vaccine synthesis were successfully integrated into standard oncologic workflows, delivering custom vaccines within a median of 9 weeks post-surgery.
-
Immunological Impact: The vaccine induced de novo high-magnitude neoantigen-specific T cells in 50% of patients. These vaccine-expanded clones comprised up to 10% of total peripheral blood T cells and persisted for up to 2 years.
-
Clinical Outcomes: Patients with vaccine-induced T-cell responses demonstrated significantly delayed disease recurrence, proving that personalized mRNA vaccines can effectively prime durable antitumor immunity in aggressive cancers.
Fig.1 Clinical and immunological profile of a resolving intrahepatic lymphoid aggregate post-vaccination.1,2
